Pralsetinib: Second Drug for RET+ NSCLC Approved in US Pralsetinib: Second Drug for RET+ NSCLC Approved in US

Another drug is now approved for use in patients with non-small cell lung cancer whose tumors harbor RET fusions, which are found in approximately 1% to 2% of cases.FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news